“Does the Salmonella Genomic Island 1 (SGI1) confer invasiveness properties to human isolates?”

BMC Infectious Diseases

Table 1 Characteristics of the strains isolated from patients infected by nontyphoidal S. enterica

Serovars	SGI1-positive n (%)	SGI1-negative n (%)
S. Typhimurium (n = 36)	7 (19.4)	29 (80.6)
DT104 (n = 9)	5 (55.6)	4 (44.4)
Non DT104 (n = 27)	2 (7.4)	25 (92.6)
Non S. Typhimurium serovars (n = 64)	5 (7.8)	59 (92.2)
S. 4, [5], 12: i- (n = 19)	0	19 (100)
S. Enteritidis (n = 14)	0	14 (100)
S. Paratyphi B var. Java (n = 2)	0	2 (100)
S. Dublin (n = 5)	0	5 (100)
Other serovars^a (n = 24)	5^b (20.8)	19 (79.2)
Phenotypes^c	SGI1-positive n (%)	SGI1-negative n (%)
Pansusceptible (n = 21)	0 (0)	21 (100)
Resistant ≥1 (n = 79)	12 (15.2)	67 (84.8)
Including penta-resistant (ACSSuT)^d (n = 9)	6 (67)	3 (33)

^aOther serovars (n = 24): S. Ahmadi (n = 1). S. Braenderup (n = 1). S. Chester (n = 2). S. Eastbourne (n = 1). S. Eboko (n = 1). S. Hadar (n = 1). S. Hessarek (n = 2); S. Infantis (n = 2); S. Kedougou (n = 1); S. Kentucky (n = 2); S. Napoli (n = 1); S. Panama (n = 1); S. Rissen (n = 1); S. Schwarzengrund (n = 2); S. Singapore (n = 1); S. St Paul (n = 3); and a new variant: 6, 7, − (n = 1)
^bOther serovars with SGI1 (n = 5): S. Infantis (n = 1), S. Kentucky (n = 2), S. St Paul (n = 2)
^cPhenotype was determined by testing amoxicillin, amoxicillin – clavulanic acid, ceftriaxone, nalidixic acid, chloramphenicol, kanamycin, spectinomycin, streptomycin, sulphonamides, trimethoprim and doxycycline in accordance to the antibiomicrobial guidelines of CASFM- EUCAST
^dACSSuT: Amoxicillin, Chloramphenicol, Streptomycin, Sulphonamides and Tetracyclines

ISSN: 1471-2334